An AKR1C3-specific prodrug with potent anti-tumor activities against T-ALL
- 24 February 2020
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 61 (7) , 1660-1668
Abstract
AKR1C3 overexpression has been reported in various types of cancers, including T-ALL. AST-006 (TH-3424), an AKR1C3-specific prodrug, was reported recently to have potent cytotoxicity against liver cancer cells overexpressing AKR1C3 and T-ALL. In this study, AST-006 demonstrated potent anti-tumor activity against different T-ALL cell lines in vitro and in vivo, including patient-derived xenograft (PDX) model. AST-006 also exhibited minimal cytotoxicity against primary human T-cells in vitro and lymphocytes in cynomolgus monkeys in vivo, indicating that AST-006 is a promising therapeutic for T-ALL.Keywords
This publication has 41 references indexed in Scilit:
- Hematopoietic cell transplantation for acute lymphoblastic leukemia in adult patientsHematology/Oncology and Stem Cell Therapy, 2017
- Leukemia-Initiating Cells in T-Cell Acute Lymphoblastic LeukemiaFrontiers in Oncology, 2017
- Aberrant Signaling Pathways in T-Cell Acute Lymphoblastic LeukemiaInternational Journal of Molecular Sciences, 2017
- Genetic Basis of Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2017
- The genetics and mechanisms of T cell acute lymphoblastic leukaemiaNature Reviews Cancer, 2016
- Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantationBlood, 2012
- Biology, Risk Stratification, and Therapy of Pediatric Acute Leukemias: An UpdateJournal of Clinical Oncology, 2011
- Modern Therapy of Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2011
- Molecular pathogenesis of T-cell leukaemia and lymphomaNature Reviews Immunology, 2008
- Oncogenic Transcription Factors in the Human Acute LeukemiasScience, 1997